Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Arterial Occlusive Diseases: full-pipeline trial registry
1 of 5 indexed Arterial Occlusive Diseases trials are currently recruiting.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Arterial Occlusive Diseases: 5 US clinical trials tracked, 1 recruiting.
Arterial Occlusive Diseases is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is ARCA Biopharma, running 2 of these trials.
Enrollment posture brief
Registry condition arterial-occlusive-diseases
OPEN 1 | RECR 20% | LATE 1 | EARLY 1 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Arterial Occlusive Diseases lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Arterial Occlusive Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Arterial Occlusive Diseases is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Arterial Occlusive Diseases research.
ARCA Biopharma accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical Arterial Occlusive Diseases enrolment sits around 230 participants.
Median target enrolment is 230 among the 5 trials that report a genuine target (sentinel values excluded). 0 of those (0%) plan for fewer than 100 participants.
-
Arterial Occlusive Diseases research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
Fundación EPIC
NCT07286578
Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries
ARCA Biopharma
NCT00115999
The Role of microRNA-210 in Regulating Oxidative Stress in Patients With PAD
University of West Florida
NCT04089943
Distributed Registry
Stanford University
NCT03898570
Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion
ARCA Biopharma
NCT00073554
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Arterial Occlusive Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Arterial Occlusive Diseases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Arterial Occlusive Diseases page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Arterial Occlusive Diseases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- ARCA Biopharma sponsors the most Arterial Occlusive Diseases trials on record, review their full trial history before evaluating a specific study. See ARCA Biopharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Arterial Occlusive Diseases condition card totals 5 registered trials; most-linked intervention Alfimeprase; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.